article thumbnail

Eckert & Ziegler and Actinium ink Ac-225 agreement

AuntMinnie

Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225). and international clinical trials.

article thumbnail

Shuttle secures more than $5M at close of public offering

AuntMinnie

Shuttle Pharmaceuticals Holdings has closed a previously announced underwritten public common stock offering, with aggregate gross proceeds of approximately $5.8 The Gaithersburg, MD-based specialty pharmaceutical company offered 19.1 million shares of its common stock at a public offering price of 30 per share.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Telix acquires assets targeting FAP in nuclear medicine

AuntMinnie

Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine. Telix said these new therapeutic assets are differentiated by a structure that drives extended tumor retention while minimizing off-target uptake.

article thumbnail

Hormone therapy linked to tau accumulation in older women

AuntMinnie

The group analyzed flortaucipir (Tauvid, Avid Pharmaceuticals) PET scans acquired over a 3.5-year Participants were clinically unimpaired and between ages 51 and 89 at the beginning of the study. The researchers aimed to investigate whether menopausal HT use is associated with later-life tau accumulation.

Disease 162
article thumbnail

First patient treated in NorthStar/Clarity clinical trial

AuntMinnie

Read more on AuntMinnie.com Related Reading: Clarity advances dose escalation for cohort in SECuRE trial Clarity reaches 50% recruitment for SABRE trial NorthStar and Bayer reach Ac-225 supply deal NorthStar manufactures Cu-67 for Clarity Pharmaceuticals NorthStar appoints new president/CEO

article thumbnail

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Imaging Technology

We are excited, in collaboration with 3BP and others, to advance this molecule through clinical testing to commercialization.” milla1cf Wed, 09/20/2023 - 09:56 September 20, 2023 — RefleXion Medical , Inc., Our partnership with 3BP is as unprecedented in the external-beam radiotherapy industry as our SCINTIX therapy is for cancer treatment.

article thumbnail

The Benefits of Coronary CTA in Pharmaceutical Clinical Trials

Imaging Technology

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than Intravascular ultrasound (IVUS), making it ideal for clinical trials of cardi